Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Apr 17, 2024

Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

Read more news from CSL

Recent News Releases
Jan 16, 2024

Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024...

Read more news from CSL Behring

Recent News Releases
May 1, 2024

Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS...

Read more news from CSL Seqirus

Recent News Releases
Apr 24, 2024

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically...

Read more news from CSL Vifor

Read all company news releases

Media Resources

Media Contacts

Victoria, Australia
Phone: +61 450 909 211

CSL Behring
North America


Asia Pacific

CSL Seqirus
EMEA and Latam
Emmanuella Dekonor
Phone: +44 7920500496

North America
Tiffany Cody
Phone: +1 908 370 1863

Asia Pacific
Hamish Walsh
Phone: 0422 424 338

CSL Plasma
United States

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • facebook icon
  • instagram icon
Get our latest news releases in your inbox
* Required Fields